Lipoprotein-associated phospholipase A2: Review of its role as a marker and a potential participant in coronary endothelial dysfunction

Molecular Diagnosis and Therapy

Volumn 11, Issue 4, 2007, Pages 219-226

  Lavi, Shahar ^a   Lavi, Ronit ^a   McConnell, Joseph P ^a   Lerman, Lilach O ^a   Lerman, Amir ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DARAPLADIB; LIPOPROTEIN; PHOSPHOLIPASE A2;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CIRCULATION; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; HUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 34548433511     PISSN: 11771062     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256243     Document Type: Review

References (71)

1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002 Mar 5; 105 (9): 1135-43
2. Tousoulis D, Charakida M, Stefanadis C. Endothelial function and inflammation in coronary artery disease. Heart 2006 Apr 1; 92 (4): 441-4
3. Albert CM, Ma J, Rifai N, et al. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002 Jun 4; 105 (22): 2595-9
4. Oei H-HS, van der Meer IM, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam study. Circulation 2005 Feb 8; 111 (5): 570-5
5. Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham heart study. Circulation 2003 Mar 25; 107 (11): 1486-91
6. Libby P. Inflammation in atherosclerosis. Nature 2002 Dec 19; 420 (6917): 868-74
7. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation 2005 Jan 25; 111 (3): 363-8
8. Lerman A, Holmes Jr DR, Bell MR, et al. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation 1995 Nov 1; 92 (9): 2426-31
9. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003 Feb 1; 23 (2): 168-75
10. Gokce N, Keaney Jr JF, Hunter LM, et al. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 2002 Apr 2; 105 (13): 1567-72
11. Widlansky ME, Gokce N, Keaney J, et al. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003 Oct 1; 42 (7): 1149-60
12. Suwaidi JA, Hamasaki S, Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000 Mar 7; 101 (9): 948-54
13. Halcox JPJ, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002 Aug 6; 106 (6): 653-8
14. Torzewski M, Rist C, Mortensen RF, et al. C-Reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000 Sep 1; 20 (9): 2094-9
15. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998 Sep 1; 98 (9): 839-44
16. O'Donoghue M, Morrow DA, Sabatine MS, et al. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation 2006 Apr 11; 113 (14): 1745-52
17. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003 Jan 28; 107 (3): 363-9
18. Vita JA, Keaney Jr JF, Larson MG, et al. Brachial artery vasodilator function and systemic inflammation in the Framingham offspring study. Circulation 2004 Dec 7; 110 (23): 3604-9
19. Kathiresan S, Gona P, Larson MG, et al. Cross-sectional relations of multiple biomarkers from distinct biological pathways to brachial artery endothelial function. Circulation 2006 Feb 21; 113 (7): 938-45
20. Hurt-Camejo E, Camejo G, Peilot H, et al. Phospholipase A2 in vascular disease. Circ Res 2001 Aug 17; 89 (4): 298-304
21. Hakkinen T, Luoma JS, Hiltunen MO, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1999 Dec 1; 19 (12): 2909-17
22. Caslake MJ, Packard CJ, Suckling KE, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 2000 Jun; 150 (2): 413-9
23. Brilakis ES, McConnell JP, Lennon RJ, et al. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 2005 Jan 2; 26 (2): 137-44
24. Yang EH, McConnell JP, Lennon RJ, et al. Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 2006 Jan 1; 26 (1): 106-11
25. Tsimikas S, Willerson JT, Ridker PM. C-Reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol 2006 Apr 18; 47 (8 Suppl. C): C19-31
26. Packard CJ, O'Reilly DSJ, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med 2000 Oct 19; 343 (16): 1148-55
27. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004 Feb 24; 109 (7): 837-42
28. 2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 2004 Oct 5; 110 (14): 1903-8
29. Blake GJ, Dada N, Fox JC, et al. A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 2001 Nov 1; 38 (5): 1302-6
30. Gerber Y, McConnell JP, Jaffe AS, et al. Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community. Arterioscler Thromb Vasc Biol 2006 Nov 1; 26 (11): 2517-22
31. Koenig W, Twardella D, Brenner H, et al. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 2006; 26 (7): 1586-93
32. Corsetti JP, Rainwater DL, Moss AJ, et al. High Lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients. Clin Chem 2006 Jul 1; 52 (7): 1331-8
33. Elkind MSV, Tai W, Coates K, et al. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med 2006 Oct 23; 166 (19): 2073-80
34. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 2005 Nov 28; 165 (21): 2479-84
35. Robins SJ, Collins D, Nelson JJ, et al. Lipoprotein-associated phospholipase A2 predicts cardiovascular events in the low HDL-C and low LDL-C population of the Veterans Affairs HDL Intervention Trial (VA-HIT) [abstract]. World Congress of Cardiology: 2006 Sep 2-5; Barcelona. Eur Heart J 2006 Aug; Suppl. 27: 3448
36. Khuseyinova N, Koenig W. Predicting the risk of cardiovascular disease: where does lipoprotein-associated phospholipase A2 fit in? Mol Diag Ther 2007; 11 (4): 203-17
37. Boekholdt SM, Keller TT, Wareham NJ, et al. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. Arterioscler Thromb Vasc Biol 2005 Apr 1; 25 (4): 839-46
38. Fichtlscherer S, Kaszkin M, Breuer S, et al. Elevated secretory non-pancreatic type II phospholipase A2 serum activity is associated with impaired endothelial vasodilator function in patients with coronary artery disease. Clin Sci 2004 May; 106 (5): 511-7
39. Lanman RB, Wolfert RL, Fleming JK, et al. Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults. Prev Cardiol 2006 Summer; 9 (3): 138-43
40. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005 May 1; 25 (5): 923-31
41. Caslake MJ, Packard CJ. Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease. Curr Opin Lipidol 2003; 14 (4): 347-52
42. Arakawa H, Qian JY, Baatar D, et al. Local expression of platelet-activating factor-acetylhydrolase reduces accumulation of oxidized lipoproteins and inhibits inflammation, shear stress-induced thrombosis, and neointima formation in balloon-injured carotid arteries in nonhyperlipidemic rabbits. Circulation 2005 Jun 21; 111 (24): 3302-9
43. Morgan EN, Boyle Jr EM, Yun W, et al. Platelet-activating factor acetylhydrolase prevents myocardial ischemia-reperfusion injury. Circulation 1999 Nov 9; 100 Suppl. II: 365II-8
44. Marathe GK, Zimmerman GA, McIntyre TM. Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles. J Biol Chem 2003 Jan 31; 278 (6): 3937-47
45. Yamada Y, Ichihara S, Fujimura T, et al. Identification of the G994 → T missense mutation in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Metabolism 1998 Feb; 47 (2): 177-81
46. Macphee CH, Nelson JJ, Zalewski A. Lipoprotein-associated phospholipase A2 as a target of therapy. Curr Opin Lipidol 2005; 16: 442-6
47. Iribarren C. Lipoprotein-associated phospholipase A2 and cardiovascular risk: state of the evidence and future directions. Arterioscler Thromb Vasc Biol 2006 Jan 1; 26 (1): 5-6
48. Gazi I, Lourida ES, Filippatos T, et al. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 2005 Dec 1; 51 (12): 2264-73
49. Meyer MC, Creer MH, McHowat J. Potential role for mast cell tryptase in recruitment of inflammatory cells to endothelium. Am J Physiol Cell Physiol 2005 Dec; 289 (6): C1485-91
50. Stulak J, Lerman A, Porcel MR, et al. Renal vascular function in hypercholesterolemia is preserved by chronic antioxidant supplementation. J Am Soc Nephrol 2001 Sep 1; 12 (9): 1882-91
51. Chade AR, Krier JD, Rodriguez-Porcel M, et al. Comparison of acute and chronic antioxidant interventions in experimental renovascular disease. Am J Physiol Renal Physiol 2004 Jun 1; 286 (6): F1079-86
52. Stafforini DM, Sheller JR, Blackwell TS, et al. Release of free F2-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases. J Biol Chem 2006 Feb 24; 281 (8): 4616-23
53. Wilson SH, Best PJM, Lerman LO, et al. Enhanced coronary vasoconstriction to oxidative stress product, 8-epi-prostaglandinF2[alpha], in experimental hypercholesterolemia. Cardiovasc Res 1999; 44 (3): 601-7
54. Kougias P, Chai H, Lin PH, et al. Lysophosphatidylcholine and secretory phospholipase A2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis. Med Sci Monit 2006 Jan; 12 (1): RA5-16
55. Liu SY, Lu X, Choy S, et al. Alteration of lysophosphatidylcholine content in low density lipoprotein after oxidative modification: relationship to endothelium dependent relaxation. Cardiovasc Res 1994 Oct; 28 (10): 1476-81
56. Inoue N, Takeshita S, Gao D, et al. Lysophosphatidylcholine increases the secretion of matrix metalloproteinase 2 through the activation of NADH/NADPH oxidase in cultured aortic endothelial cells. Atherosclerosis 2001 Mar; 155 (1): 45-52
57. Safaya R, Chai H, Kougias P, et al. Effect of lysophosphatidylcholine on vasomotor functions of porcine coronary arteries. J Surg Res 2005 Jun 15; 126 (2): 182-8
58. Takahashi M, Okazaki H, Ogata Y, et al. Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38-mitogen-activated protein kinase-dependent mechanism. Atherosclerosis 2002/4; 161 (2): 387-94
59. Chaudhuri P, Colles SM, Damron DS, et al. Lysophosphatidylcholine inhibits endothelial cell migration by increasing intracellular calcium and activating calpain. Arterioscler Thromb Vasc Biol 2003; 23 (2): 218-23
60. Eizawa H, Yui Y, Inoue R, et al. Lysophosphatidylcholine inhibits endothelium-dependent hyperpolarization and N{omega}-nitro-L-arginine/ indomethacin resistant endothelium-dependent relaxation in the porcine coronary artery. Circulation 1995 Dec 15; 92 (12): 3520-6
61. Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003 Aug 20; 290 (7): 898-904
62. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005 Apr 7; 352 (14): 1425-35
63. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004 Apr 8; 350 (15): 1495-504
64. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z Trial. JAMA 2004 Sep 15; 292 (11): 1307-16
65. Iribarren C, Gross MD, Darbinian JA, et al. Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study. Arterioscler Thromb Vasc Biol 2005 Jan 1; 25 (1): 216-21
66. Schaefer EJ, McNamara JR, Asztalos BF, et al. Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. Am J Cardiol 2005 May 1; 95 (9): 1025-32
67. Blackie JA, Bloomer JC, Brown MJB, et al. The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2. Bioorg Med Chem Lett 2003 Mar 24; 13 (6): 1067-70
68. Shi Y, Zhang P, Zhang L, et al. Role of lipoprotein-associated phospholipase A(2) in leukocyte activation and inflammatory responses. Atherosclerosis 2007 Mar; 191 (1): 54-62
69. Zhang P, Zhang L, Carabasi A, et al. 258/B109-oxidized LDL-induced upregulation of IL-18 in monocytes/macrophages is modulated by lipoprotein-associated phospholipase A2: potential mechanism of inflammatory burden in atherosclerosis [abstract]. American Heart Association Scientific Sessions; 2006 Nov 12-15; Chicago (IL)
70. SB-480848 in subjects with coronary heart disease [online]. Available from URL: http://clinicaltrials.gov/ct/show/NCT00269048 [Accessed 2007 Jul 5]
71. Kolodgie FD, Burke AP, Skorija KS, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006 Nov 1; 26 (11): 2523-9